β-Elemene inhibits the metastasis of B16F10 melanoma cells by downregulation of the expression of uPA, uPAR, MMP-2, and MMP-9

Melanoma Research

Volumn 24, Issue 2, 2014, Pages 99-107

  Shi, Hong ^a   Liu, Lei ^a   Liu, Limin ^a   Geng, Jin ^a   Zhou, Yun ^a   Chen, Lei ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

Matrix metalloproteinase 2; Matrix metalloproteinase 9; Melanoma cell; Urokinase type plasminogen activator; Urokinase type plasminogen activator receptor; elemene

Indexed keywords

BETA ELEMENE; GELATINASE A; GELATINASE B; MESSENGER RNA; UROKINASE; UROKINASE RECEPTOR; BETA-ELEMENE; MMP2 PROTEIN, MOUSE; MMP9 PROTEIN, MOUSE; SESQUITERPENE;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CELL VIABILITY; CONCENTRATION RESPONSE; DOWN REGULATION; DRUG MECHANISM; IMMUNOCYTOCHEMISTRY; MELANOMA CELL; METASTASIS; MOUSE; MTT ASSAY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING; ANIMAL; BIOSYNTHESIS; CELL MOTION; ENZYMOLOGY; GENETICS; MELANOMA, EXPERIMENTAL; PATHOLOGY; PHYSIOLOGY; SKIN NEOPLASMS; TUMOR CELL LINE; TUMOR INVASION;

ANIMALS; CELL LINE, TUMOR; CELL MOVEMENT; DOWN-REGULATION; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MELANOMA, EXPERIMENTAL; MICE; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; RECEPTORS, UROKINASE PLASMINOGEN ACTIVATOR; RNA, MESSENGER; SESQUITERPENES; SKIN NEOPLASMS; UROKINASE-TYPE PLASMINOGEN ACTIVATOR;

EID: 84896394861     PISSN: 09608931     EISSN: 14735636     Source Type: Journal    
DOI: 10.1097/CMR.0000000000000043     Document Type: Article

References (49)

1. Jerant AF, Johnson JT, Sheridan CD, Caffrey TJ. Early detection and treatment of skin cancer. Am Fam Physician 2000; 62: 357-368.
2. Jahng AW, Liao SS. Successful palliation with octreotide of a neuroendocrine syndrome from malignant melanoma. J Pain Symptom Manage 2006; 32: 191-195.
3. Guadagnolo BA, Zagars GK. Adjuvant radiation therapy for high-risk nodal metastases from cutaneous melanoma. Lancet Oncol 2009; 10: 409-416.
4. ChenW, Lu Y,Wu J, Gao M,Wang A, Xu B. Beta-elemene inhibits melanoma growth and metastasis via suppressing vascular endothelial growth factor mediated angiogenesis. Cancer Chemother Pharmacol 2011; 67: 799-808.
5. Tan W, Lu J, Huang M, Li Y, Chen M, Wu G, et al. Anti-cancer natural products isolated from Chinese medicinal herbs. Chin Med 2011; 6: 27-41.
6. Gaudi S, Messina JL. Molecular bases of cutaneous and uveal melanomas. Patholog Res Int 2011; 10: 4061-4069.
7. Wang L, Madigan MC, Chen H, Liu F, Patterson KI, Beretov J, et al. Expression of urokinase plasminogen activator and its receptor in advanced epithelial ovarian cancer patients. Gynecol Oncol 2009; 114: 265-272.
8. Blasi F, Sidenius N. The urokinase receptor: focused cell surface proteolysis, cell adhesion and signaling. FEBS Lett 2010; 584: 1923-1930.
9. Ossowski L, Aguirre-Ghiso JA. Urokinase receptor and integrin partnership: coordination of signaling for cell adhesion, migration and growth. Cur Opin Cell Biol 2000; 12: 613-620.
10. Blasi F, Carmeliet P. uPAR: a versatile signaling orchestrator. Nat Rev Mol Cell Biol 2002; 3: 932-943.
11. Nguyen DH, Hussaini IM, Gonias SL. Binding of urokinase type plasminogen activator to its receptor in MCF-7 cells activates extracellular signal-regulated kinase 1 and 2 which is required for increased cellular motility. J Biol Chem 1998; 273: 8502-8507.
12. Aguirre Ghiso JA, Kovalski K, Ossowski L. Tumor dormancy induced by downregulation of urokinase receptor in human carcinoma involves integrin and MAPK signaling. J Cell Biol 1999; 147: 89-104.
13. Mignatti P, Rifkin DB. Plasminogen activators and matrix metalloproteinases in angiogenesis. Enzyme Protein 1996; 49: 117-137.
14. Bauer TW, Liu W, Fan F, Camp ER, Yang A, Somcio RJ, et al. Targeting of urokinase plasminogen activator receptor in human pancreatic carcinoma cells inhibits c-Met - and insulin-like growth factor-I receptor-mediated migration and invasion and orthotopic tumor growth in mice. Cancer Res 2005; 65: 7775-7781.
15. Weng CJ, Yen GC. The in vitro and in vivo experimental evidences disclose the chemopreventive effects of Ganoderma lucidum on cancer invasion and metastasis. Clin Exp Metastasis 2010; 27: 361-369.
16. Zhang C, Zhou SS, Feng LY, Zhang DY, Lin NM, Zhang LH, et al. In vitro anticancer activity of chamaejasmenin B and neochamaejasmin C isolated from the root of Stellera chamaejasme L. Acta Pharmacol Sin 2012; 10: 1038-1058.
17. Liu J, Zhang Y. b-Elemene induced autophagy protects human gastric cancer cells from undergoing apoptosis. BMC Cancer 2011; 11: 183.
18. Zhang R, Tian A, Shi X, Yu H, Chen L. Downregulation of IL-17 and IFN-g in the optic nerve by b-elemene in experimental autoimmune encephalomyelitis. Int Immunopharmacol 2011; 10: 738-743.
19. Li QQ, Wang G, Zhang M, Cuff CF, Huang L, Reed E. b-Elemene, a novel plant-derived antineoplastic agent, increases cisplatin chemo-sensitivity of lung tumor cells by triggering apoptosis. Oncol Rep 2009; 22: 161-170.
20. Wang G, Li X, Huang F, Zhao J, Ding H, Cunningham C, et al. Antitumor effect of beta-elemene in non-small-cell lung cancer cells is mediated via induction of cell cycle arrest and apoptotic cell death. Cell Mol Life Sci 2005; 62: 881-893.
21. Xie CY, Yang W, Li M, Ying J, Tao SJ, Li K, et al. Cell apoptosis induced by delta elemene in colorectal adenocarcinoma cells via a mitochondrialmediated pathway. Yakugaku Zasshi 2009; 129: 1403-1413.
22. Yao YQ, Ding X, Jia YC, Huang CX, Wang YZ, Xu YH. Anti-tumor effect of beta-elemene in glioblastoma cells depends on p38 MAPK activation. Cancer Lett 2008; 264: 127-134.
23. Wang J, Zhang H, Sun Y. Phase III clinical trial of elemene emulsion in the management of malignant pleural and peritoneal effusions. Zhonghua Zhong Liu Za Zhi 1996; 18: 464-467.
24. Tan P, ZhongW, CaiW. Clinical study on treatment of 40 cases of malignant brain tumor by elemene emulsion injection. Zhongguo Zhong Xi Yi Jie He Za Zhi 2000; 20: 645-648.
25. Li X,Wang G, Zhao J, Ding H, Cunningham C, Chen F, et al. Antiproliferative effect of beta-elemene in chemoresistant ovarian carcinoma cells is mediated through arrest of the cell cycle at the G2-M phase. Cell Mol Life Sci 2005; 62: 894-904.
26. Li QQ, Wang G, Reed E, Huang L, Cuff CF. Evaluation of cisplatin in combination with beta-elemene as a regimen for prostate cancer chemotherapy. Basic Clin Pharmacol Toxicol 2010; 107: 868-876.
27. Yang HL, Kuo YH, Tsai CT, Huang YT, Chen SC, Chang HW, et al. Anti-metastatic activities of Antrodia camphorata against human breast cancer cells mediated through suppression of the MAPK signaling pathway. Food Chem Toxicol 2011; 49: 290-298.
28. Schostak M, Krause H, Miller K, Schrader M, Weikert S, Christoph F, et al. Quantitative real-time RT-PCR of CD24 mRNA in the detection of prostate cancer. BMC Urol 2006; 15: 1-7.
29. Chen LX, He YJ, Zhao SZ,Wu JG,Wang JT, Zhu LM, et al. Inhibition of tumor growth and vasculogenic mimicry by curcumin through downregulation of the EphA2/PI3K/MMP pathway in a murine choroidal melanoma model. Cancer Biol Ther 2011; 11: 229-235.
30. Cicek M, Fukuyama R, Welch DR, Sizemore N, Casey G. Breast cancer metastasis suppressor I inhibits gene expression by targeting nuclear factorkappaB activity. Cancer Res 2005; 65: 3586-3595.
31. Cicek M, Fukuyama R, Cicek MS, Sizemore S,Welch DR, Sizemore N, et al. BRMS1 negatively regulates NF-kB-dependent uPA expression following recruitment of HDAC1 to the NF-kB binding site of the uPA promoter. Clin Exp Metastasis 2009; 26: 29-37.
32. Fujiwara K, Takatsu H, Tsukamoto K. Immunocytochemistry for drugs containing an aliphatic primary amino group in the molecule, anticancer antibiotic Daunomycin as a model. J Histochem Cytochem 2005; 53: 467-474.
33. Zhu X, Guo K, Lu Y. Selenium effectively inhibits 1,2- dihydroxynaphthaleneinduced apoptosis in human lens epithelial cells through activation of PI3-K/Akt pathway. Mol Vis 2011; 17: 2019-2027.
34. Siripong P, Rassamee K, Piyaviriyakul S, Yahuafai J, Kanokmedhakul K. Anti-metastatic effects on B16F10 melanoma cells of extracts and two prenylated xanthones isolated from Maclura amboinensis Bl roots. Asian Pac J Cancer Prev 2012; 13: 3519-3528.
35. Ogasawara M, Matsunaga T, Takahashi S, Saiki I, Suzuki H. Anti-invasive and metastatic activities of evodiamine. Biol Pharm Bull 2002; 25: 1491-1493.
36. Liu JW, Sun P, Yan Q, Paller AS, Gerami P, Ho N, et al. De-N-acetyl GM3 promotes melanoma cell migration and invasion through urokinase plasminogen activator receptor signaling dependent MMP-2 activation. Cancer Res 2009; 69: 8662-8669.
37. Pupa SM, Mé nard S, Forti S, Tagliabue E. New insights into the role of extracellular matrix during tumor onset and progression. J Cell Physiol 2002; 192: 259-267.
38. He Y, Liu XD, Chen ZY, Zhu J, Xiong Y, Li K, et al. Interaction between cancer cells and stromal fibroblasts is required for activation of the uPAR-uPA-MMP-2 cascade in pancreatic cancer metastasis. Clin Cancer Res 2007; 13: 3115-3124.
39. Duffy MJ. The urokinase plasminogen activator system: role in malignancy. Curr Pharm Des 2004; 10: 9-49.
40. Choong PF, Nadesapillai AP. Urokinase plasminogen activator system: a multi functional role in tumor progression and metastasis. Clin Orthop Relat Res 2003; 415: S46-S58.
41. Andreasen PA, Kjøller L, Christensen L, Duffy MJ. The urokinase-type plasminogen activator system in cancer metastasis: a review. Int J Cancer 1997; 72: 1-22.
42. Lijnen HR. Pleiotropic functions of the plasminogen activator inhibitor-1. J Thromb Haemost 2005; 3: 35-45.
43. Sidenius N, Blasi F. The urokinase plasminogen activator system in cancer: recent advances and implication for prognosis and therapy. Cancer Metastasis Rev 2003; 22: 205-222.
44. Danø K, Behrendt N. Plasminogen activation and cancer. Thromb Haemost 2005; 93: 676-681.
45. Pepper MS. Role of matrix metalloproteinases and plasminogen activator plasmin system in angiogenesis. Arterioscler Thromb Vasc Biol 2001; 21: 1104-1117.
46. Ulisse1 S, Baldini E. The urokinase plasminogen activator system: a target for anti-cancer therapy. Curr Cancer Drug Targets 2009; 9: 32-71.
47. Zhao Y, Lyons CE Jr, Xiao A, Templeton DJ, Sang QA, Brew K, et al. Urokinase directly activates matrix metalloproteinases-9: a potential role in glioblastoma invasion. Biochem Biophy Res Commun 2008; 369: 1215-1220.
48. Graves LE, Ariztia EV, Navari JR, Matzel HJ, Stack MS, Fishman DA. Proinvasive properties of ovarian cancer ascites-derived membrane vesicles. Cancer Res 2004; 64: 7045-7049.
49. Schmalfeldt B, Prechtel D, Hä rting K, Spä the K, Rutke S, Konik E, et al. Increased expression of matrix metalloproteinases (MMP)-2, MMP-9, and the urokinase-type plasminogen activator is associated with progression from benign to advanced ovarian cancer. Clin Cancer Res 2001; 7: 2396-2404.